Cargando…
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†)
AIMS: This multicentre, randomized trial compared three strategies of AF ablation: ablation of complex fractionated electrograms (CFE) alone, pulmonary vein isolation (PVI) alone, and combined PVI + CFE ablation, using standardized automated mapping software. METHODS AND RESULTS: Patients with drug-...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878965/ https://www.ncbi.nlm.nih.gov/pubmed/20215126 http://dx.doi.org/10.1093/eurheartj/ehq041 |
_version_ | 1782181898889461760 |
---|---|
author | Verma, Atul Mantovan, Roberto Macle, Laurent De Martino, Guiseppe Chen, Jian Morillo, Carlos A. Novak, Paul Calzolari, Vittorio Guerra, Peter G. Nair, Girish Torrecilla, Esteban G. Khaykin, Yaariv |
author_facet | Verma, Atul Mantovan, Roberto Macle, Laurent De Martino, Guiseppe Chen, Jian Morillo, Carlos A. Novak, Paul Calzolari, Vittorio Guerra, Peter G. Nair, Girish Torrecilla, Esteban G. Khaykin, Yaariv |
author_sort | Verma, Atul |
collection | PubMed |
description | AIMS: This multicentre, randomized trial compared three strategies of AF ablation: ablation of complex fractionated electrograms (CFE) alone, pulmonary vein isolation (PVI) alone, and combined PVI + CFE ablation, using standardized automated mapping software. METHODS AND RESULTS: Patients with drug-refractory, high-burden paroxysmal (episodes >6 h, >4 in 6 months) or persistent atrial fibrillation (AF) were enrolled at eight centres. Patients (n = 100) were randomized to one of three arms. For CFE alone (n = 34), spontaneous/induced AF was mapped using validated, automated CFE software and all sites <120 ms were ablated until AF termination/non-inducibility. For PVI (n = 32), all four PV antra were isolated and confirmed using a circular catheter. For PVI + CFE (n = 34), all four PV antra were isolated, followed by AF induction and ablation of all CFE sites until AF termination/non-inducibility. Patients were followed at 3, 6, and 12 months with a visit, ECG, 48 h Holter. Atrial fibrillation symptoms were confirmed by loop recording. Repeat procedures were allowed within the first 6 months. The primary endpoint was freedom from AF >30 s at 1 year. Patients (age 57 ± 10 years, LA size 42 ± 6 mm) were 35% persistent AF. In CFE, ablation terminated AF in 68%. Only 0.4 PVs per patient were isolated as a result of CFE. In PVI, 94% had all four PVs successfully isolated. In PVI + CFE, 94% had all four PVs isolated, 76% had inducible AF with additional CFE ablation, with 73% termination of AF. There were significantly more repeat procedures in the CFE arm (47%) vs. PVI (31%) or PVI + CFE (15%) (P = 0.01). After one procedure, PVI + CFE had a significantly higher freedom from AF (74%) compared with PVI (48%) and CFE (29%) (P = 0.004). After two procedures, PVI + CFE still had the highest success (88%) compared with PVI (68%) and CFE (38%) (P = 0.001). Ninety-six percent of these patients were off anti-arrhythmics. Complications were two tamponades, no PV stenosis, and no mortality. CONCLUSION: In high-burden paroxysmal/persistent AF, PVI + CFE has the highest freedom from AF vs. PVI or CFE alone after one or two procedures. Complex fractionated electrogram alone has the lowest one and two procedure success rates with a higher incidence of repeat procedures. ClinicalTrials.gov identifier number NCT00367757. |
format | Text |
id | pubmed-2878965 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28789652010-06-02 Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†) Verma, Atul Mantovan, Roberto Macle, Laurent De Martino, Guiseppe Chen, Jian Morillo, Carlos A. Novak, Paul Calzolari, Vittorio Guerra, Peter G. Nair, Girish Torrecilla, Esteban G. Khaykin, Yaariv Eur Heart J Clinical Research AIMS: This multicentre, randomized trial compared three strategies of AF ablation: ablation of complex fractionated electrograms (CFE) alone, pulmonary vein isolation (PVI) alone, and combined PVI + CFE ablation, using standardized automated mapping software. METHODS AND RESULTS: Patients with drug-refractory, high-burden paroxysmal (episodes >6 h, >4 in 6 months) or persistent atrial fibrillation (AF) were enrolled at eight centres. Patients (n = 100) were randomized to one of three arms. For CFE alone (n = 34), spontaneous/induced AF was mapped using validated, automated CFE software and all sites <120 ms were ablated until AF termination/non-inducibility. For PVI (n = 32), all four PV antra were isolated and confirmed using a circular catheter. For PVI + CFE (n = 34), all four PV antra were isolated, followed by AF induction and ablation of all CFE sites until AF termination/non-inducibility. Patients were followed at 3, 6, and 12 months with a visit, ECG, 48 h Holter. Atrial fibrillation symptoms were confirmed by loop recording. Repeat procedures were allowed within the first 6 months. The primary endpoint was freedom from AF >30 s at 1 year. Patients (age 57 ± 10 years, LA size 42 ± 6 mm) were 35% persistent AF. In CFE, ablation terminated AF in 68%. Only 0.4 PVs per patient were isolated as a result of CFE. In PVI, 94% had all four PVs successfully isolated. In PVI + CFE, 94% had all four PVs isolated, 76% had inducible AF with additional CFE ablation, with 73% termination of AF. There were significantly more repeat procedures in the CFE arm (47%) vs. PVI (31%) or PVI + CFE (15%) (P = 0.01). After one procedure, PVI + CFE had a significantly higher freedom from AF (74%) compared with PVI (48%) and CFE (29%) (P = 0.004). After two procedures, PVI + CFE still had the highest success (88%) compared with PVI (68%) and CFE (38%) (P = 0.001). Ninety-six percent of these patients were off anti-arrhythmics. Complications were two tamponades, no PV stenosis, and no mortality. CONCLUSION: In high-burden paroxysmal/persistent AF, PVI + CFE has the highest freedom from AF vs. PVI or CFE alone after one or two procedures. Complex fractionated electrogram alone has the lowest one and two procedure success rates with a higher incidence of repeat procedures. ClinicalTrials.gov identifier number NCT00367757. Oxford University Press 2010-06 2010-03-09 /pmc/articles/PMC2878965/ /pubmed/20215126 http://dx.doi.org/10.1093/eurheartj/ehq041 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/2.0/uk/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org. |
spellingShingle | Clinical Research Verma, Atul Mantovan, Roberto Macle, Laurent De Martino, Guiseppe Chen, Jian Morillo, Carlos A. Novak, Paul Calzolari, Vittorio Guerra, Peter G. Nair, Girish Torrecilla, Esteban G. Khaykin, Yaariv Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†) |
title | Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†) |
title_full | Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†) |
title_fullStr | Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†) |
title_full_unstemmed | Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†) |
title_short | Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial(†) |
title_sort | substrate and trigger ablation for reduction of atrial fibrillation (star af): a randomized, multicentre, international trial(†) |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878965/ https://www.ncbi.nlm.nih.gov/pubmed/20215126 http://dx.doi.org/10.1093/eurheartj/ehq041 |
work_keys_str_mv | AT vermaatul substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT mantovanroberto substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT maclelaurent substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT demartinoguiseppe substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT chenjian substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT morillocarlosa substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT novakpaul substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT calzolarivittorio substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT guerrapeterg substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT nairgirish substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT torrecillaestebang substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial AT khaykinyaariv substrateandtriggerablationforreductionofatrialfibrillationstarafarandomizedmulticentreinternationaltrial |